Product Highlight - BLENREP

Both BVd and BPd are recommended by NICE for patients with previously treated multiple myeloma^1,2

• BVd: Demonstrated a superior median PFS versus DVd (36.6 vs 13.4 months), reducing the risk of progression or death by 59% (HR 0.41; 95% CI, 0.31-0.53).³
• BVd: Modelled analyses predict a median OS of 84 months.⁴
• BPd: More than doubled median PFS versus PVd (32.6 vs 12.5 months), reducing the risk of progression or death by 51% (HR 0.49; 95% CI, 0.35-0.68).⁵

BVd=Belantamab mafodotin plus bortezomib and dexamethasone, BPd=Belantamab mafodotin plus pomalidomide and dexamethasone, HR=Hazard ratio, CI=Confidence interval

Most common AEs (any grade): Corneal exam findings (including keratopathy), reduced visual acuity, thrombocytopenia, blurred vision, dry eye, foreign body sensation in eyes, photophobia, eye irritation, neutropenia, anaemia, diarrhoea, neuropathies, eye pain.

References:
1. NICE. TA1149. Apr 2026. https://www.nice.org.uk/guidance/ta1149. Accessed Jul 2026.
2. NICE. TA1133. Feb 2026. https://www.nice.org.uk/guidance/ta1133. Accessed Jul 2026.
3. BLENREP Prescribing Information. GSK Hong Kong. 2026.
4. Hungria V, et al. DREAMM-7. ASH 2024. Abstract #772.
5. Dimopoulos MA, et al. DREAMM-8. EHA 2025. Abstract PF728.

Please read the full prescribing information prior to administration. Full prescribing information is available upon request.

For adverse event reporting, please call GlaxoSmithKline Limited at (852) 3189 8989 (Hong Kong), or report via online Patient Safety reporting form: https://gsk.public.reportum.com/.

2026 GSK group of companies or its licensor. Trademarks are owned by or licensed to the GSK group of companies. The material is for the reference and use by healthcare professional only.


QR code is linked to PI.
PM-HK-BLM-DRIS-260001
Date of preparation: 07/2026 (06/2028)